Saudi Medical Devices Law: Royal Decree No. M/54

1. Key takeaways

Royal Decree No. M/54 is the only legal-tier document in the Saudi medical device regulatory system, signed on Hijri 1442/7/6 (18 February 2021) and promulgated in Umm Al-Qura issue No. 4872 (26 February 2021). Its core role is not to prescribe procedures but to deliver definitions that cannot be overridden by private agreement, and to authorise SFDA to land the principles through Board decrees and the MDS-REQ series. For Chinese manufacturers the correct way to use M/54 is three things — cite the definitions, fix the responsible entity, draw the boundaries — not to search it for dossier checklists; those sit in the Implementing Regulation and MDS-REQ1. Penalty article numbers and fine ranges were not officially corroborated in this review and must be handled as a practical estimate, verified separately.

• Article 1 of M/54 defines in one sweep Medical Device, Medical Supply, Establishment, Manufacturer, Authorized Representative, Circulation, License, MDNR, Registration, Marketing Authorization and the other official concepts.
• The Manufacturer definition counts refurbishing, assembly, packaging and labelling as manufacturing, so a trade house that only applies its own label may be a statutory manufacturer.
• The Authorized Representative must be a legal entity located in Saudi Arabia holding written authorisation from the foreign manufacturer, ruling out offshore entities.
• Articles (14), (16), (20), (28), (30) and (31) of M/54 are cited by MDS-REQ 11 V2.0 as its legal basis for reprocessing, second-hand device resale, lending and donation, after-sales and maintenance, and final destruction.

2. Legal basis

The table lists the instruments this guide traces back to Royal Decree No. M/54, with the article numbers and points on which downstream files rely.

3. Expert insights

Article 1 is the most valuable provision in the entire text

Article 1 defines in one sweep Medical Device, Medical Supply, Establishment, Manufacturer, Health Care Provider, Authorized Representative, Circulation, License, MDNR, Registration, Marketing Authorization, Certificate of Free Sale, Verification of Clinical Studies, Classification System, Quality Management System, Innovative, Assembled and Single-use devices, Radioactive Material, Fraudulent device and Reprocessing. GRZAN finds most registration-response disputes come back to how one word in Article 1 is read. Three examples: the Manufacturer definition counts refurbishing, assembly, packaging and labelling as manufacturing, so a distributor doing only own-brand labelling may be a statutory manufacturer; the AR is confined to a legal entity within Saudi Arabia holding written authorisation, so an AR cannot be offshore; and the Single-use definition stresses one-time use on a patient in a single medical procedure, the starting point for judging reprocessing legality. At every Saudi project kick-off GRZAN runs every attribute of the intended product — sterile or not, measuring function or not, reusable surgical instrument or not, IVD or not, innovative or not — against the Article 1 definitions; if any of the five is yes, the pathway changes, and a Class A device answering no to all five may take the lighter MDNR route while everything else takes the full MDMA.

How the definitional provisions decide the licence holder and the allocation of responsibility

Article 1 defines Marketing Authorization as the SFDA document permitting a device to circulate on the market, and Registration as the procedure of entering the device and the enterprise in the MDNR. Read side by side, the two show a dual system of enterprise listing plus product authorisation. MDS-G011 V2.0 states further that SFDA issues the MDMA certificate in the manufacturer’s name, which matters greatly when changing an AR: the certificate sits with the manufacturer, so a change of AR does not carry the MDMA away. The design is commercially sensitive: local distributors often ask for the MDMA in their own name, but under MDS-G011 the licence holder can only be the manufacturer, which protects the manufacturer’s position at the price of building its own traceable documentation and vigilance capability rather than outsourcing the obligations to the AR or a distributor. Under the EU MDR, the EC-REP is merely a contact point within the EU and the CE certificate likewise belongs to the manufacturer; the US FDA 510(k) holder may be the specification developer, a different subject logic. China’s NMPA registrant is a domestic entity and foreign manufacturers must appoint a domestic responsible person — the closest parallel to the Saudi AR design, but the Saudi AR needs a separate licence and carries a longer duty list.

What the two-tier structure of legal authorisation and implementing regulation means

M/54 states principles only. Article 3 authorises the SFDA Board to adopt the Implementing Regulation, Article 8 forms the basis of subsequent detailed rules, and Articles 14, 16, 20, 28, 30 and 31 set the legal basis for post-market obligations directly — MDS-REQ 11 V2.0 was made by invoking exactly those articles. Operationally, when a reviewer demands supplementary documents the demand cites an MDS-REQ entry, but its binding force traces up to an article of M/54. Manufacturers answering only at the MDS-REQ level without escalating to the legal tier often lack a superior basis when appealing. Conversely, penalty details not captured in M/54 must never be estimated from experience; flag them as a practical estimate and check against SFDA or the original gazette.

The procedural articles implementing M/54 authorisation are analysed at https://www.grzan.cn/regulations/saudi/implementing-regulation-decree-3-29-1443-03 , and the legal basis of post-market obligations at https://www.grzan.cn/regulations/saudi/post-market-surveillance-ncmdr-and-saudi-vigilance-41 .

4. Practical recommendations

• Translate all Article 1 definitions into a bilingual reference table as the internal terminology baseline, and use the same wording in every external document (powers of attorney, agreements, technical files).
• Assess whether the company is a statutory Manufacturer: where refurbishing, assembly, packaging or labelling takes place, Article 1 already treats it as manufacturing, and QMS and technical documentation must meet the manufacturer’s obligations.
• The AR agreement must embody both elements — a legal entity within Saudi Arabia and written authorisation from the foreign manufacturer — since missing either fails the Article 1 definition.
• Cite M/54 with the fixed formulation Law of Medical Devices and Supplies, Royal Decree No. M/54, Article (X), with both Hijri and Gregorian dates, avoiding conflation with the Implementing Regulation.
• Mark statements about penalties, fines or enforcement practice as a practical estimate, and verify Umm Al-Qura issue No. 4872 via the SFDA website or the gazette.
• For reprocessing, second-hand device resale, lending or donation, after-sales maintenance and final destruction, build internal compliance procedures traced back to M/54 Articles (14), (16), (20), (28), (30) and (31).
• For an innovative device, pre-assess against the Article 1 definition of an Innovative Medical Device (novel in technology, intended use or performance, and not previously placed on local or international markets) whether additional material is needed.

5. Verification checklist

• □ Obtained the official English translation of M/54, checking the dual dates Hijri 1442/7/6 and 18 February 2021
• □ All Article 1 definitions translated and incorporated into the corporate glossary
• □ The company’s manufacturing and labelling activities characterised against the Manufacturer definition
• □ AR agreement contains the elements of a domestic legal entity and written authorisation
• □ Internal citation template unified to the format M/54, Article (X)
• □ Penalty content flagged as a practical estimate and listed as a pending verification item
• □ The six post-market businesses mapped to Articles 14, 16, 20, 28, 30 and 31
• □ Innovative devices pre-assessed against the Innovative definition

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages SFDA medical device marketing authorisations and Saudi Authorized Representative arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com